ICU admission (n = 13) | No ICU admission (n = 80) | Univariable odds ratio | 95% CI | p-value | Multivariable odds ratio | 95% CI | p-value | |
---|---|---|---|---|---|---|---|---|
Age, median (IQR), years | 47 (40–63) | 58 (43–66) | 0.98 | 0.94–1.01 | 0.212 | |||
Male | 6 (46%) | 43 (54%) | 0.74 | 0.23–2.39 | 0.612 | |||
CDS-VRE, median (IQR) | 1.9 (1.5–3.6) | 1.9 (1.8–3.4) | 1.02 | 0.67–1.55 | 0.932 | |||
Hematological malignancy | 12 (92%) | 69 (86%) | 1.91 | 0.23–16.21 | 0.552 | |||
AlloBMT | 6 (46%) | 18 (23%) | 2.95 | 0.88–9.90 | 0.080 | 0.96 | 0.16–5.96 | 0.968 |
Antibiotic days prior to BSI, median (IQR) | 20 (18–29) | 16 (9–26) | 1.03 | 0.99–1.08 | 0.163 | 1.02 | 0.97–1.08 | 0.399 |
ICU admissionb | 4 (31%) | 25 (31%) | 0.98 | 0.28–3.48 | 0.972 | |||
Hypoalbuminemia daysb, median (IQR) | 18 (14–30) | 17 (9–29) | 1.03 | 0.97–1.09 | 0.380 | |||
Mucositis grade, median (IQR) | 3 (0–4) | 0 (0–2) | 1.60 | 1.11–2.30 | 0.011 | 1.81 | 1.04–3.14 | 0.036 |
Polymicrobial BSI | 3 (23%) | 18 (23%) | 1.03 | 0.26–4.16 | 0.963 | |||
Neutropenia at time of BSI | 9 (69%) | 66 (83%) | 0.48 | 0.13–1.77 | 0.269 | |||
Teicoplanin monotherapy | 4 (31%) | 55 (69%) | 0.23 | 0.06–0.83 | 0.024 | 0.14 | 0.03–0.66 | 0.013 |